Skip to main content

$0.040 -0.002 (-4.76%)

High

$0.04

Low

$0.04

Trades

59

Turnover

$28,759

Volume

696,012
30 June 2023 at 4:10pm
Register to track ACW and receive email alerts.
Subject
ACW Ann: ACW CEO presentation on emerging oral Alzheimers therapies

ACW Ann: ACW CEO & CMO present at BIO International Convention

ACW Ann: ACW AD trial amendment and Clinical Science Forum slides

ACW Ann: Quarterly Activity Report & Appendix 4C

ACW Ann: Actinogen CMO presents at ADPD 2023 conference

ACW Ann: Application for quotation of securities - ACW

ACW Ann: Appendix 3X - Dr Nicki Vasquez

ACW Ann: ACW appoints Dr Nicki Vasquez as a Non-Executive Director

ACW Ann: Actinogen CEO presents to Spark Plus Biotech conference

ACW Ann: Appendix 4D & Half-Year Financial Statements

ACW Ann: Actinogen appoints Dr Dana Hilt as Chief Medical Officer

ACW Ann: Quarterly Activity Report & Appendix 4C

ACW Ann: ACW CEO presentation Sachs Neuroscience and JPM week

ACW Ann: Letter to Shareholders - CEO 2022 Review & Outlook

ACW Ann: FDA agrees to six-month Phase 2b Alzheimers Disease Trial

ACW Ann: Cleansing Notice

ACW Ann: Application for quotation of securities - ACW

ACW Ann: First patient treated in XanaCIDD Phase 2 Depression Trial

ACW Ann: Actinogen poster presentation at CTAD conference 2022

ACW Ann: Constitution

ACW Ann: Results of AGM

ACW Ann: Actinogen AGM Chair address & CEO presentation

ACW Ann: Appendix 3Y - Dr George Morstyn

ACW Ann: Cleansing Notice

ACW Ann: Application for quotation of securities - ACW

ACW Ann: ACW CEO presentation to Bell Potter Healthcare Conference

ACW Ann: Appendix 3Y - Dr Steven Gourlay

ACW Ann: Actinogen CEO presentation to Spark Plus Healthcare Day

ACW Ann: Quarterly Activity Report & Appendix 4C

ACW Ann: Actinogen CEO presentation to ShareCafe investor webinar

ACW Ann: R&D tax incentive rebate received

ACW Ann: Annual Report to Shareholders

ACW Ann: Letter to Shareholders, Notice of AGM & Proxy Form

ACW Ann: ACW clinical biomarker study webcast presentation

ACW Ann: ACW announces positive Alzheimers Disease clinical results

ACW Ann: Trading Halt

ACW Ann: Date of AGM and Closing Date for Director Nominations

ACW Ann: Actinogen AD Biomarkers Context & History Presentation

ACW Ann: Appendix 4G

ACW Ann: Corporate Governance Statement

ACW Ann: Actinogen FY22 Results - Accelerating Clinical Development

ACW Ann: ACW Appendix 4E and 2022 Annual Report

ACW Ann: Actinogen Spark Plus non deal roadshow investor presentation

ACW Ann: Actinogen Clinical Trials Science Forum presentation slides

ACW Ann: ACW CEO presentation to Spark Plus Aust Equities Day

ACW Ann: Quarterly Activity Report & Appendix 4C

ACW Ann: ACW CEO to present at Spark Plus Aust Equities Day

ACW Ann: Actinogen Clinical Trials Science Forum Save the Date

ACW Ann: Application for quotation of securities - ACW

ACW Ann: Actinogen Alzheimer Disease Biomarker Study Timing & Design

Register to track ACW and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX